The proportions of using dual-antiplatelet therapy (P = 0.018), GP IIb/IIIa inhibitors (P < 0.001), and proton pump inhibitors (P = 0.012) were significantly higher in the BP-DES group than in the G2-DES group in patients without DM (Table 1). The gene discussed is ITGA2B; the disease is diabetes mellitus.